Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 1/2006

01-01-2006 | Original Article

Longitudinal MicroPET Imaging of Brain Tumor Growth with F-18-labeled RGD Peptide

Authors: Xiaoyuan Chen, PhD, Ryan Park, BS, Vazgen Khankaldyyan, BS, Ignacio Gonzales-Gomez, MD, Michel Tohme, MS, Rex A. Moats, PhD, James R. Bading, PhD, Walter E. Laug, MD, Peter S. Conti, MD, PhD

Published in: Molecular Imaging and Biology | Issue 1/2006

Login to get access

Abstract

Purpose

EMD 121974, a potent cyclic RGD peptide inhibitor of α v-integrins, demonstrated effectiveness in suppressing brain tumor growth in both preclinical models and phases I/II clinical trials. The ability to non-invasively evaluate α v-integrin expression provides a novel and unique way to better understand brain tumor angiogenesis in relationship to α v-integrin expression, and allow for direct assessment of anti-integrin treatment efficacy.

Procedures

We developed a F-18-labeled RGD peptide [F-18]FB-RGD and performed serial microPET imaging scans to follow brain tumor growth and angiogenesis as a function of time in an orthotopic U87MG glioblastoma xenograft model in athymic nude mice.

Results

The tumor was barely visible on microPET at the size of ≤1.5 mm diameter at which time no angiogenesis was evident on histological examination. When tumor started to grow exponentially by day 35 the activity accumulation in the brain tumor also increased accordingly, with best tumor-to-brain contrast seven weeks after inoculation of 105 U87MG cells into the mice forebrain.

Conclusions

Longitudinal microPET imaging and [F-18]FB-RGD provides the sensitivity and resolution to visualize and quantify anatomical variations during brain tumor growth and angiogenesis, most likely through interaction with α v-integrins expressed on tumor cells and angiogenic tumor vessels.
Literature
1.
2.
Boiardi A, Silvani A, Pozzi A, et al. (1997) Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. J Neuro-Oncol 34:179–185CrossRef
3.
Puduvalli VK, Yung AW (1998) New frontiers in therapy of malignant gliomas. Forum 8:261–269PubMed
4.
Puduvalli VK, Sawaya R (2000) Antiangiogenesis—therapeutic strategies and clinical implications for brain tumors. J Neuro-Oncol 50:189–200CrossRef
5.
Taga T, Suzuki A, Gonzalez-Gomez I, et al. (2002) Alpha(v)-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98:690–697CrossRefPubMed
6.
MacDonald TJ, Taga T, Shimada H, et al. (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha-v integrin antagonist. Neurosurgery 48:151–157CrossRefPubMed
7.
Cristofanilli M, Charnsangavej C, Hortobagyi GN (2002) Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 1:415–426CrossRef
8.
Anderson SA, Rader RK, Westlin WF, et al. (2000) Magnetic resonance contrast enhancement of neovasculature with α v β 3-targeted nanoparticles. Magn Reson Med 44:433–439CrossRefPubMed
9.
Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998) Detection of tumor angiogenesis in vivo by α v β 3-targeted magnetic resonance imaging. Nat Med 4:623–626CrossRefPubMed
10.
Chen X, Park R, Shahinian AH, Bading JR, Conti PS (2004) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31:11–19CrossRefPubMed
11.
Chen X, Park R, Shahinian AH, et al. (2004) 18F-labeled RGD peptide: Initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 31:179–189CrossRefPubMed
12.
Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS (2004) MicroPET and autoradiographic imaging of breast cancer α v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15:41–49CrossRefPubMed
13.
Chen X, Park R, Hou Y, et al. (2004) MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 31:1081–1089CrossRefPubMed
14.
Chen X, Tohme M, Park R, Hou Y, Bading JR, Conti PS (2004) MicroPET imaging of α v β 3 integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging 3:96–104CrossRefPubMed
15.
Chen X, Hou Y, Tohme M, et al. (2004) PEGylated RGD peptide: 64Cu-labeleing and PET imaging of brain tumor integrin α v β 3 expression. J Nucl Med 45:1776–1783PubMed
16.
Chen X, Liu S, Hou Y, et al. (2004) MicroPET imaging of breast cancer α v-integrin expression with 64Cu-labeled dimeric RGD Peptides. Mol Imaging Biol 6:350–359CrossRefPubMed
17.
Hauber R, Kuhnast B, Mang C, et al. (2004) [18F]Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15:61–69CrossRefPubMed
18.
Haubner R, Wester HJ, Weber WA, et al. (2001) Noninvasive imaging of α v β 3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781–1785PubMed
19.
Haubner R, Wester HJ, Burkhart F, et al. (2001) Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 42:326–336PubMed
20.
Haubner R, Wester HJ, Reuning U, et al. (1999) Radiolabeled α v β 3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med 40:1061–1071PubMed
21.
Janssen M, Oyen WJ, Massuger LF, et al. (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 17:641–646CrossRefPubMed
22.
Janssen ML, Oyen WJ, Dijkgraaf I, et al. (2002) Tumor targeting with radiolabeled α v β 3 integrin binding peptides in a nude mouse model. Cancer Res 62:6146–6151PubMed
23.
Van Hagen PM, Breeman WA, Bernard HF, et al. (2000) Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy. Int J Cancer 90:186–198CrossRefPubMed
24.
Ellegala DB, Leong-Poi H, Carpenter JE, et al. (2003) Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to α v β 3. Circulation 108:336–341CrossRefPubMed
25.
Greenberg HS, Chandler WF, Sandler HM (1999) Brain Tumors (Contemporary Neurology Series, 54). New York: Oxford University Press.
26.
Spence AM, Muzi M, Krohn KA (2002) Molecular imaging of regional brain tumor biology. J Cell Biochem 39(Suppl):25–35CrossRef
27.
Blouw B, Song H, Tihan T (2003) The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4:133–146CrossRefPubMed
28.
Holash J, Maisonpierre PC, Compton D, et al. (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998CrossRefPubMed
29.
Zagzag D, Amirnovin R, Greco MA, et al. (2000) Vascular apoptosis and involution in gliomas precede neovascularization: A novel concept for glioma growth and angiogenesis. Lab Invest 80:837–849PubMed
30.
31.
Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin α v β 3 for angiogenesis. Science 264:569–571PubMedCrossRef
32.
Balaban RS, Hampshire VA (2001) Challenges in small animal noninvasive imaging. ILAR J 42:248–262PubMed
33.
Toyama H, Ichise M, Liow JS, et al. (2004) Evaluation of anesthesia effects on [18F]FDG uptake in mouse brain and heart using small animal PET. Nucl Med Biol 31:251–256CrossRefPubMed
Metadata
Title
Longitudinal MicroPET Imaging of Brain Tumor Growth with F-18-labeled RGD Peptide
Authors
Xiaoyuan Chen, PhD
Ryan Park, BS
Vazgen Khankaldyyan, BS
Ignacio Gonzales-Gomez, MD
Michel Tohme, MS
Rex A. Moats, PhD
James R. Bading, PhD
Walter E. Laug, MD
Peter S. Conti, MD, PhD
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 1/2006
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-005-0024-1

Other articles of this Issue 1/2006

Molecular Imaging and Biology 1/2006 Go to the issue

Original Article

Combined I-124 Positron Emission Tomography/Computed Tomography Imaging of NIS Gene Expression in Animal Models of Stably Transfected and Intravenously Transfected Tumor

Research Article

Reduction of Brown Fat 2-Deoxy-2-[F-18]fluoro-d-glucose Uptake by Controlling Environmental Temperature Prior to Positron Emission Tomography Scan

Original Article

Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [C-11]Desipramine, [C-11]Talopram and [C-11]Talsupram

Original Article

Positron Emission Tomography/Computed Tomography with F-18-fluorocholine for Restaging of Prostate Cancer Patients: Meaningful at PSA < 5 ng/ml?

Research Article

Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy

Research Article

Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus